Kevin Chow, PhD

Dr. Kevin Chow serves as our Co-founder, President & CEO and has over two decades of experience leading business development, corporate strategy and operations in the biopharmaceutical industry. His experience spans both large cap and small emerging biotechnology companies, where he enjoys bridging the gap between cutting edge bioscience and venture development from platform technologies through to Phase 3 development programs. Before Mitera, he was co-founder, President and CEO of Vitaeris (acquired by CSL Behring), a biotechnology company conducting a multi-national Phase 3 study in kidney transplant rejection. Prior to co-founding Vitaeris in early 2016, Dr. Chow served as Head of Business Development at Alder Biopharmaceuticals (acquired by Lundbeck), where he led partnering efforts for Alder’s monoclonal antibody pipeline. Previously, Dr. Chow led pulmonary in-licensing at Gilead Sciences and served as Director of Business Development for Corus Pharma, a specialty pharmaceutical company focused on cystic fibrosis and asthma drug development. From 2000-2003 Dr. Chow served in various business development roles with Diversa Corporation.

Dr. Chow concurrently supports business strategy for Incisive Genetics, focused on lipid nanoparticle delivery of CRISPR genome editing and is an advisor to the Seattle-based venture capital firm Accelerator Life Science Partners.

Dr. Chow holds B.Sc., M.Sc., and Ph.D. degrees in Microbiology and Immunology from the University of British Columbia in Vancouver, Canada.